Scientific deep-dive

BPC-157 for Gut Health & Leaky Gut: What the Evidence Shows

BPC-157 is the most-studied peptide in gastrointestinal research — yet every controlled experiment is in rats. We map the NSAID-protection, colitis, fistula, and leaky-gut evidence alongside the human RCT gap.

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed
9 min read·10 citations

BPC-157 (body protection compound-157) is a synthetic 15-amino-acid peptide originally isolated from human gastric juice — making the gut its most studied biological domain. Decades of animal research document impressive cytoprotection against NSAID-induced injury, colitis, fistulas, and anastomosis failure. Yet despite this preclinical depth, no human randomized controlled trial has tested BPC-157 for any gastrointestinal indication, and the "leaky gut" claim — perhaps its most widely marketed use — rests on animal intestinal-permeability data that has never been replicated in a controlled human study. This article maps what the evidence actually shows: the strongest preclinical gut story in peptide research, and the human evidence gap that means every claim must carry that caveat. See our BPC-157 guide for the companion overview of how it works and what it costs. Status as of October 2026: in a draft policy, HHS says it does not intend to bring enforcement action against those 503A pharmacies that compound single-ingredient BPC-157 under ten conditions, oral and topical forms included. Oral products carry an extra condition: the compounder holds records proving that its particular formulation is absorbed well enough by mouth in people[9]. The Federal Register notice calls it a draft, non-binding policy with a two-week comment window, not a rule[10]. It is not FDA approval for any gut condition. Our explainer on the HHS 503A peptide policy and news report cover the details, and our BPC-157 provider page lists current options.

BPC-157's gut origins: a gastric peptide from the start

BPC-157 was first identified in the 1990s by Predrag Sikiric and colleagues at the University of Zagreb as a partial sequence of human gastric juice protein. Unlike many research peptides developed for a specific receptor target, BPC-157 emerged from the gut itself — which is why the stomach and intestines remain its most extensively studied organ system. The peptide's original name — body protection compound — reflects the broad cytoprotective effects first observed in gastric mucosa models. Over thirty years of preclinical work have since expanded that picture to the entire gastrointestinal tract: from esophagus to colon, including fistula healing and anastomosis repair[2].

That preclinical breadth is real and notable by peptide-research standards. What it is not is human clinical evidence. Every controlled experiment documenting these GI effects was conducted in rats or mice under standardized laboratory injury models. The animal-to-human translational gap is a recurring theme in BPC-157 research and is explicitly acknowledged in recent systematic reviews[7][8].

NSAID-induced gut injury: the most documented preclinical effect

The strongest single line of BPC-157 GI evidence involves non-steroidal anti-inflammatory drug (NSAID) toxicity. NSAIDs — including aspirin, ibuprofen, diclofenac, and indomethacin — damage the gastric and intestinal mucosa by inhibiting prostaglandin synthesis, disrupting the mucosal barrier, and increasing intestinal permeability. In animal models, BPC-157 consistently counteracts these effects. A 2020 study by Park et al. in Current Pharmaceutical Design demonstrated that BPC-157 "rescued NSAID-cytotoxicity via stabilizing intestinal permeability and enhancing cytoprotection" in rodents[1], documenting both barrier protection and cellular recovery at the mucosal level. This is mechanistically coherent: the peptide modulates nitric oxide systems and VEGFR2 signaling in ways that support mucosal repair and microvascular integrity.

Lojo et al.'s 2016 PLoS One study extended this picture to a surgically challenging model — 24-hour short-bowel rats treated with diclofenac[4]. In these animals, diclofenac produced gastrointestinal, liver, and brain lesions while worsening intestinal adaptation; BPC-157 counteracted each of these effects. That multi-organ protection in a combined surgical/pharmacological stress model illustrates why BPC-157 has attracted preclinical attention: it appears to act at multiple failure points simultaneously, rather than blocking a single pathway.

Colitis and IBD animal models

BPC-157 has been tested in rodent models of colitis using acetic acid, TNBS (2,4,6-trinitrobenzenesulfonic acid), and other chemical inducers of intestinal inflammation — the standard preclinical surrogates for inflammatory bowel disease (IBD). In these models, BPC-157 consistently reduces mucosal damage scores, inflammatory markers, and histological injury. Sikiric's group has published extensively on this across multiple decades, and the 2024 Inflammopharmacology review synthesizes that literature under the framework of GI cytoprotection and vascular protection, noting that BPC-157 counteracts the vascular and multiorgan failure associated with severe gut injury[2].

It is important to be clear about what "IBD model" means and what it does not mean. Acetic acid colitis in rats is a useful research tool for studying intestinal inflammation. It is not the same as Crohn's disease or ulcerative colitis in a human patient with a complex immune history, comorbidities, and years of disease. No human with IBD has been treated with BPC-157 in a published clinical trial, and no animal-colitis result should be interpreted as evidence that BPC-157 will benefit a human with Crohn's or UC.

Fistula and anastomosis healing in animal models

Two of the more surgically relevant animal-model applications involve fistulas and intestinal anastomoses. A fistula is an abnormal connection between two body structures — a recognized complication of IBD, radiation, surgery, and trauma. Sikiric et al.'s 2020 review in Current Pharmaceutical Design documents BPC-157 therapy across multiple fistula types in animal models, arguing that the peptide promotes healing of cutaneous, esophageal, colocutaneous, and other fistulas in rats[5]. Healing rates and inflammatory markers consistently favored BPC-157 over control conditions in those experiments.

Bajramagic et al.'s 2024 review in Pharmaceuticals specifically covers intestinal anastomosis therapy in rats — that is, the healing of surgically created intestinal connections[3]. Anastomosis failure (leakage) is a serious surgical complication; anything that reliably improved anastomosis healing in humans would be clinically meaningful. The animal data across multiple experiments is consistent: BPC-157 improves anastomosis healing speed and strength in rats. Whether this translates to any clinical benefit remains entirely untested in humans.

The brain-gut axis: BPC-157's bidirectional signaling

A 2023 paper by Sikiric et al. in Pharmaceuticals proposes that BPC-157 may recover function along both the brain-gut axis (central nervous system influencing gut) and the gut-brain axis (gut influencing central nervous system)[6]. The brain-gut axis is a well-established bidirectional communication network linking the enteric nervous system to the central nervous system via vagal, hormonal, and immune pathways. Disruption of this axis is implicated in IBS, functional dyspepsia, and stress-related GI symptoms. In animal experiments, BPC-157 modulated dopamine, serotonin, and nitric oxide systems in ways that affected both gastrointestinal motility and neurological outcomes simultaneously. This pleiotropic signaling profile is interesting mechanistically but remains entirely preclinical.

"Leaky gut" — real physiology, not a standalone diagnosis

"Leaky gut" or intestinal hyperpermeability is a real, measurable physiological phenomenon. The intestinal lining acts as a selective barrier — allowing nutrients to pass while blocking pathogens, toxins, and large molecules. This barrier is maintained by tight junctions between enterocytes. When those junctions break down (as happens with NSAIDs, alcohol, stress, certain infections, and inflammatory conditions), intestinal permeability increases, allowing larger molecules to transit the gut lining. This can be measured with lactulose/mannitol ratios and other validated assays.

What is not an established medical diagnosis is "leaky gut syndrome" as a distinct condition responsible for fatigue, food sensitivities, autoimmune disease, autism, depression, and other systemic complaints — a cluster of claims popular in wellness marketing. Mainstream gastroenterology recognizes increased intestinal permeability as a feature of certain conditions (Crohn's disease, celiac disease, critical illness) rather than a standalone diagnosis that can be treated in isolation. The American Gastroenterological Association and similar bodies have not endorsed "leaky gut syndrome" as a clinical entity.

BPC-157's relevance here is specific: in NSAID-injury animal models, it demonstrably stabilizes intestinal permeability at the tight-junction level[1]. That is a real and measurable preclinical effect. What it does not establish is that BPC-157 reverses "leaky gut syndrome" in humans, reduces food sensitivities, or treats any of the systemic complaints attributed to intestinal hyperpermeability in wellness contexts. The leap from "stabilizes NSAID-induced permeability changes in rats" to "heals leaky gut in humans" is not supported by any published controlled evidence. The permeability peptide that does have human trials is larazotide, studied in celiac disease, and even it stopped short of approval when its Phase 3 was terminated.

The human evidence gap

For all the depth of its preclinical GI literature, BPC-157 has not been tested in a single completed, published human randomized controlled trial for any gastrointestinal indication. No Phase I dose-finding study for GI use, no Phase II safety-and-efficacy trial for IBD or IBS or fistula healing, no registered ongoing trial that is known to be active. A 2025 multifunctionality review by Józwiak et al. in Pharmaceuticals confirmed this translational gap across all BPC-157 indications[7]: an extensive preclinical literature paired with an essentially absent human clinical database.

The 2025 systematic review by Vasireddi et al. in the HSS Journal, though focused on orthopedic sports medicine, explicitly identified BPC-157's popularity as outpacing its evidence base and flagged the reliance on unregulated, non-pharmaceutical-grade sources as a central safety concern[8]. Those findings apply equally to gut-health use: people are obtaining gray-market BPC-157 on the basis of animal studies that — however consistent — have never been replicated in controlled human trials. For gut use the route matters too: our review of oral BPC-157 vs injection covers what is known about absorption by mouth.

BPC-157 gut-health evidence map — claim, evidence base, and model type
Gut claimEvidence baseModel type
NSAID-induced gut injury protectionMultiple studies show mucosal barrier stabilization and cytoprotection; Park 2020 specifically documents intestinal permeability rescue[1]Rats/mice; pharmacological injury model
Intestinal permeability ("leaky gut") stabilizationBPC-157 maintains tight-junction integrity in NSAID and stress models[1][2]Rats; no human measurement data
Colitis / IBD-like inflammationReduced mucosal damage scores and inflammatory markers in acetic acid and TNBS colitis models[2]Rats; chemical-induction models; no human IBD trial
Intestinal anastomosis healingConsistent improvement in anastomosis strength and healing speed across multiple rat-model experiments[3]Rats; surgical models; no human surgical trial
Fistula healingEsophageal, cutaneous, and colocutaneous fistula healing documented across animal experiments[5]Rats; no human fistula trial
Short-bowel syndrome / NSAID+surgery combinationProtected against GI, liver, and brain lesions in combined diclofenac + short-bowel surgery rat model[4]Rats; combined pharmacological/surgical model
Brain-gut and gut-brain axis dysfunctionModulation of dopamine, serotonin, and NO systems with bidirectional GI/CNS effects proposed[6]Rats; no human functional GI trial
IBD/IBS/functional GI disorders in humansNo published human RCT. Zero completed controlled trials for any human GI indication[7][8]N/A — no human controlled data

Animal data only — plus gray-market and regulatory cautions

Every gut-protection result cited in this article comes from rats or mice. No randomized controlled trial has tested BPC-157 in any human gastrointestinal condition. Beyond the evidence gap, there are concrete regulatory concerns: BPC-157 is not FDA-approved for any use; it was in FDA’s Category 2 from September 2023 until April 22, 2026, and compounded single-ingredient versions have been covered only by a draft, interim HHS enforcement-discretion policy since October 2026, which is not approval[9]; and gray-market peptide products sold online carry no verification of identity, purity, dose, or sterility. Injecting an unregulated product on the basis of animal data carries real risks — contamination, incorrect dose, and infection — that are entirely independent of whether BPC-157's preclinical GI effects are genuine.

Frequently Asked Questions

In animal models, yes — it consistently shows gut-protective effects including reduced mucosal damage from NSAIDs, improved healing in colitis models, and faster fistula and anastomosis repair. In humans, we do not know: no randomized controlled trial has been conducted for any gastrointestinal indication. The preclinical evidence is the strongest in peptide research for a GI application, but animal results do not automatically transfer to humans, and none of these effects have been demonstrated in a controlled human study.
In NSAID-injury rat models, BPC-157 demonstrably stabilizes intestinal permeability at the tight-junction level — that is a real preclinical finding. However, 'leaky gut syndrome' is not a recognized standalone medical diagnosis, and no human study has shown that BPC-157 reduces intestinal permeability or resolves any of the systemic symptoms attributed to it in wellness marketing. The jump from 'stabilizes NSAID-induced permeability in rats' to 'heals leaky gut in people' has no controlled human evidence behind it.
Animal colitis models (acetic acid, TNBS) consistently show BPC-157 reduces mucosal damage and inflammation markers. There is no completed human trial in Crohn's disease, ulcerative colitis, or IBS. Chemical colitis in rats is a useful research model but is not the same disease as IBD in a human patient. Until human trials are conducted, there is no evidence-based answer to whether BPC-157 helps IBD or IBS in people.
No. As of mid-2026, no completed, published randomized controlled trial has tested BPC-157 for any gastrointestinal indication in humans. There are no known active registered Phase II GI trials. The entire human evidence base for BPC-157 — across all indications — amounts to fewer than 30 subjects in three small uncontrolled pilot studies (none focused on the gut), according to a 2026 pharmaceutical development review.
Peptides are typically degraded in the stomach and small intestine before absorption, which raises real questions about oral bioavailability. Some proponents argue that gut-lining effects might not require systemic absorption — that local mucosal contact could be sufficient — and there are animal experiments using oral and intragastric BPC-157. But oral bioavailability in humans has not been formally characterized, no oral-capsule formulation has been tested in a human clinical trial, and claims that oral BPC-157 reaches systemic circulation intact are speculative. The draft October 2026 HHS compounding policy covers oral BPC-157 only if the pharmacy keeps documentation that its specific formulation reaches adequate oral bioavailability in humans.
Increased intestinal permeability is a real, measurable physiological state — tight junctions between gut-lining cells can become disrupted, increasing the passage of molecules across the gut wall. This is documented in Crohn's disease, celiac disease, and critical illness. What mainstream gastroenterology does not recognize is 'leaky gut syndrome' as a distinct clinical diagnosis responsible for systemic conditions like fatigue, food intolerances, or autoimmune disease. Intestinal permeability is a feature of certain recognized conditions, not a standalone diagnosis — and there is no approved treatment specifically targeting it.
There is no evidence-based answer, because BPC-157 has not been tested for any gut condition in a controlled human trial — so any specific timeframe is unproven. The healing timelines and protocols circulating online are anecdotal, not derived from human data, and the animal studies that show gut effects cannot be translated into a reliable human schedule. BPC-157 is not FDA-approved and is sold through unregulated channels, so a clinician is the right person to consult about any gut symptom rather than an online protocol.
No peptide has been shown in robust human trials to 'heal leaky gut,' and 'leaky gut' itself is a loosely defined, contested concept rather than a settled clinical diagnosis. Increased intestinal permeability is real and measurable, but it is generally a feature of recognized conditions rather than a standalone problem with an approved peptide treatment. For BPC-157 specifically, the permeability data is animal-only, so marketing that presents peptides as a proven fix for leaky gut goes beyond the evidence — discuss persistent gut symptoms with a clinician.
We do not provide dosing or protocols, because there is no human-trial evidence to base them on — the routes, doses, and durations shared in online communities are anecdotal, not clinically validated. BPC-157 is not FDA-approved, and the draft, interim HHS compounding policy announced in October 2026 sets no dose. Research-chemical products sold for this purpose are unregulated and unverified for identity, purity, and dose. If you are dealing with a gut issue, the appropriate step is to work with a clinician on evidence-based options rather than a self-administered peptide.

References

  1. 1.Park JM, Lee HJ, Sikiric P, Hahm KB. BPC 157 Rescued NSAID-cytotoxicity Via Stabilizing Intestinal Permeability and Enhancing Cytoprotection. Curr Pharm Des. 2020. PMID: 32445447.
  2. 2.Sikiric P, Sever M, Krezic I, Vranes H, Kalogjera L, Smoday IM, Vukovic V, Oroz K, Coric L, Skoro M, Kavelj I, Zubcic S, Sikiric S, Beketic Oreskovic L, Oreskovic I, Blagaic V, Brcic K, Strbe S, Staresinic M, Boban Blagaic A, Skrtic A, Seiwerth S. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Significance of counteraction of vascular and multiorgan failure of occlusion/occlusion-like syndrome in cytoprotection/organoprotection. Inflammopharmacology. 2024. PMID: 38980576.
  3. 3.Bajramagic S, Sever M, Rasic F, Staresinic M, Skrtic A, Beketic Oreskovic L, Oreskovic I, Strbe S, Loga Zec S, Hrabar J, Coric L, Prenc M, Blagaic V, Brcic K, Boban Blagaic A, Seiwerth S, Sikiric P. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats — A Review. Pharmaceuticals (Basel). 2024. PMID: 39204186.
  4. 4.Lojo N, Rasic Z, Zenko Sever A, Kolenc D, Vukusic D, Drmic D, Zoricic I, Sever M, Seiwerth S, Sikiric P. Effects of Diclofenac, L-NAME, L-Arginine, and Pentadecapeptide BPC 157 on Gastrointestinal, Liver, and Brain Lesions, Failed Anastomosis, and Intestinal Adaptation Deterioration in 24 Hour-Short-Bowel Rats. PLoS One. 2016. PMID: 27627764.
  5. 5.Sikiric P, Drmic D, Sever M, Klicek R, Blagaic AB, Tvrdeic A, Kralj T, Kovac KK, Vukojevic J, Siroglavic M, Gojkovic S, Krezic I, Pavlov KH, Rasic D, Mirkovic I, Kokot A, Skrtic A, Seiwerth S. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des. 2020. PMID: 32329684.
  6. 6.Sikiric P, Gojkovic S, Krezic I, Smoday IM, Kalogjera L, Zizek H, Oroz K, Vranes H, Vukovic V, Labidi M, Strbe S, Baketic Oreskovic L, Sever M, Tepes M, Knezevic M, Barisic I, Blagaic V, Vlainic J, Dobric I, Staresinic M, Skrtic A, Jurjevic I, Boban Blagaic A, Seiwerth S. Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Brain Axis Function. Pharmaceuticals (Basel). 2023. PMID: 37242459.
  7. 7.Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide. Pharmaceuticals (Basel). 2025. PMID: 40005999.
  8. 8.Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. PMID: 40756949.
  9. 9.U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A and Appendix B). HHS. 2026. https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
  10. 10.U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice; Docket No. HHS-OASH-2026-0496; FR Doc. 2026-22192. Federal Register. 2026. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances

Larazotide for Leaky Gut & Celiac Disease: The Real Clinical Evidence

Larazotide acetate (AT-1001) is the most clinically studied intestinal-permeability peptide, with multiple human RCTs in celiac disease — but its Phase 3 was terminated and it remains unapproved.

12 min read

KPV for Gut Inflammation and IBD: What the Mouse Colitis Studies Show

KPV, a fragment of alpha-MSH, is marketed for IBD and gut health, but the evidence is preclinical only: mouse colitis models and cell culture, with no human trial. It is not FDA-approved. A draft October 2026 HHS policy would not enforce against topical and oral 503A compounding.

9 min read

KPV Capsules, Cream or Injection? Route, Evidence and What the HHS Policy Covers

KPV capsules, creams and injections compared by route. The draft HHS 503A policy covers only topical and oral KPV, and oral forms need documented human bioavailability. What mouse and lab skin studies show, and why injectable KPV falls outside the policy.

9 min read

Wegovy with Crohn's and Ozempic with Ulcerative Colitis: GLP-1 in IBD Evidence Review

Stable Crohn's or ulcerative colitis does not appear to rule out GLP-1 receptor agonists: in Nanah 2026, GLP-1 users had fewer IBD flares than a bariatric-surgery cohort. No established interaction with 5-ASA, biologics, or immunomodulators. Active flare is not the time to start.

13 min read

Are Peptides Legal? 2026 Rules for Compounded vs Research Peptides

FDA-approved peptide drugs are legal by prescription. A draft October 2026 HHS policy says HHS does not intend to enforce against 503A compounding of six peptides, including BPC-157 and TB-500, under ten conditions. Research-chemical peptides are still not legal for human use.

12 min read

BPC-157 for Weight Loss: What the Evidence Actually Shows

BPC-157 is sold as a research peptide and marketed for weight loss, but there is no FDA approval, no human randomized trial, and no mechanism for fat loss. We review the (animal-only) evidence, the regulatory reality, and how it compares to FDA-approved obesity drugs.

8 min read

Where to get GLP-1 safely: vetted online providers

Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

Pricing Compare

Get started →
8.3

Found

Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help

Read full review →

Pricing Compare

Get started →
8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

Pricing Compare

Get started →